PortalPublikationenTherapygenetic effects of 5-HTTLPR on cognitive-behavioral t...

Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis

Standard

Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis. / Schiele, Miriam A; Reif, Andreas; Lin, Jiaxi; Alpers, Georg W; Andersson, Evelyn; Andersson, Gerhard; Arolt, Volker; Bergström, Jan; Carlbring, Per; Eley, Thalia C; Esquivel, Gabriel; Furmark, Tomas; Gerlach, Alexander L; Hamm, Alfons; Helbig-Lang, Sylvia; Hudson, Jennifer L; Lang, Thomas; Lester, Kathryn J; Lindefors, Nils; Lonsdorf, Tina B; Pauli, Paul; Richter, Jan; Rief, Winfried; Roberts, Susanna; Rück, Christian; Schruers, Koen R J; Thiel, Christiane; Wittchen, Hans-Ulrich; Domschke, Katharina; Weber, Heike; Lueken, Ulrike.

in: EUR NEUROPSYCHOPHARM, Jahrgang 44, 03.2021, S. 105-120.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schiele, MA, Reif, A, Lin, J, Alpers, GW, Andersson, E, Andersson, G, Arolt, V, Bergström, J, Carlbring, P, Eley, TC, Esquivel, G, Furmark, T, Gerlach, AL, Hamm, A, Helbig-Lang, S, Hudson, JL, Lang, T, Lester, KJ, Lindefors, N, Lonsdorf, TB, Pauli, P, Richter, J, Rief, W, Roberts, S, Rück, C, Schruers, KRJ, Thiel, C, Wittchen, H-U, Domschke, K, Weber, H & Lueken, U 2021, 'Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis', EUR NEUROPSYCHOPHARM, Jg. 44, S. 105-120. https://doi.org/10.1016/j.euroneuro.2021.01.004

APA

Schiele, M. A., Reif, A., Lin, J., Alpers, G. W., Andersson, E., Andersson, G., Arolt, V., Bergström, J., Carlbring, P., Eley, T. C., Esquivel, G., Furmark, T., Gerlach, A. L., Hamm, A., Helbig-Lang, S., Hudson, J. L., Lang, T., Lester, K. J., Lindefors, N., ... Lueken, U. (2021). Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis. EUR NEUROPSYCHOPHARM, 44, 105-120. https://doi.org/10.1016/j.euroneuro.2021.01.004

Vancouver

Schiele MA, Reif A, Lin J, Alpers GW, Andersson E, Andersson G et al. Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis. EUR NEUROPSYCHOPHARM. 2021 Mär;44:105-120. https://doi.org/10.1016/j.euroneuro.2021.01.004

Bibtex

@article{d1bdc1e2530f4ffc87f5a27494f63f31,
title = "Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis",
abstract = "There is a recurring debate on the role of the serotonin transporter gene linked polymorphic region (5-HTTLPR) in the moderation of response to cognitive behavioral therapy (CBT) in anxiety disorders. Results, however, are still inconclusive. We here aim to perform a meta-analysis on the role of 5-HTTLPR in the moderation of CBT outcome in anxiety disorders. We investigated both categorical (symptom reduction of at least 50%) and dimensional outcomes from baseline to post-treatment and follow-up. Original data were obtained from ten independent samples (including three unpublished samples) with a total of 2,195 patients with primary anxiety disorder. No significant effects of 5-HTTLPR genotype on categorical or dimensional outcomes at post and follow-up were detected. We conclude that current evidence does not support the hypothesis of 5-HTTLPR as a moderator of treatment outcome for CBT in anxiety disorders. Future research should address whether other factors such as long-term changes or epigenetic processes may explain further variance in these complex gene-environment interactions and molecular-genetic pathways that may confer behavioral change following psychotherapy.",
author = "Schiele, {Miriam A} and Andreas Reif and Jiaxi Lin and Alpers, {Georg W} and Evelyn Andersson and Gerhard Andersson and Volker Arolt and Jan Bergstr{\"o}m and Per Carlbring and Eley, {Thalia C} and Gabriel Esquivel and Tomas Furmark and Gerlach, {Alexander L} and Alfons Hamm and Sylvia Helbig-Lang and Hudson, {Jennifer L} and Thomas Lang and Lester, {Kathryn J} and Nils Lindefors and Lonsdorf, {Tina B} and Paul Pauli and Jan Richter and Winfried Rief and Susanna Roberts and Christian R{\"u}ck and Schruers, {Koen R J} and Christiane Thiel and Hans-Ulrich Wittchen and Katharina Domschke and Heike Weber and Ulrike Lueken",
note = "Copyright {\textcopyright} 2021. Published by Elsevier B.V.",
year = "2021",
month = mar,
doi = "10.1016/j.euroneuro.2021.01.004",
language = "English",
volume = "44",
pages = "105--120",
journal = "EUR NEUROPSYCHOPHARM",
issn = "0924-977X",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis

AU - Schiele, Miriam A

AU - Reif, Andreas

AU - Lin, Jiaxi

AU - Alpers, Georg W

AU - Andersson, Evelyn

AU - Andersson, Gerhard

AU - Arolt, Volker

AU - Bergström, Jan

AU - Carlbring, Per

AU - Eley, Thalia C

AU - Esquivel, Gabriel

AU - Furmark, Tomas

AU - Gerlach, Alexander L

AU - Hamm, Alfons

AU - Helbig-Lang, Sylvia

AU - Hudson, Jennifer L

AU - Lang, Thomas

AU - Lester, Kathryn J

AU - Lindefors, Nils

AU - Lonsdorf, Tina B

AU - Pauli, Paul

AU - Richter, Jan

AU - Rief, Winfried

AU - Roberts, Susanna

AU - Rück, Christian

AU - Schruers, Koen R J

AU - Thiel, Christiane

AU - Wittchen, Hans-Ulrich

AU - Domschke, Katharina

AU - Weber, Heike

AU - Lueken, Ulrike

N1 - Copyright © 2021. Published by Elsevier B.V.

PY - 2021/3

Y1 - 2021/3

N2 - There is a recurring debate on the role of the serotonin transporter gene linked polymorphic region (5-HTTLPR) in the moderation of response to cognitive behavioral therapy (CBT) in anxiety disorders. Results, however, are still inconclusive. We here aim to perform a meta-analysis on the role of 5-HTTLPR in the moderation of CBT outcome in anxiety disorders. We investigated both categorical (symptom reduction of at least 50%) and dimensional outcomes from baseline to post-treatment and follow-up. Original data were obtained from ten independent samples (including three unpublished samples) with a total of 2,195 patients with primary anxiety disorder. No significant effects of 5-HTTLPR genotype on categorical or dimensional outcomes at post and follow-up were detected. We conclude that current evidence does not support the hypothesis of 5-HTTLPR as a moderator of treatment outcome for CBT in anxiety disorders. Future research should address whether other factors such as long-term changes or epigenetic processes may explain further variance in these complex gene-environment interactions and molecular-genetic pathways that may confer behavioral change following psychotherapy.

AB - There is a recurring debate on the role of the serotonin transporter gene linked polymorphic region (5-HTTLPR) in the moderation of response to cognitive behavioral therapy (CBT) in anxiety disorders. Results, however, are still inconclusive. We here aim to perform a meta-analysis on the role of 5-HTTLPR in the moderation of CBT outcome in anxiety disorders. We investigated both categorical (symptom reduction of at least 50%) and dimensional outcomes from baseline to post-treatment and follow-up. Original data were obtained from ten independent samples (including three unpublished samples) with a total of 2,195 patients with primary anxiety disorder. No significant effects of 5-HTTLPR genotype on categorical or dimensional outcomes at post and follow-up were detected. We conclude that current evidence does not support the hypothesis of 5-HTTLPR as a moderator of treatment outcome for CBT in anxiety disorders. Future research should address whether other factors such as long-term changes or epigenetic processes may explain further variance in these complex gene-environment interactions and molecular-genetic pathways that may confer behavioral change following psychotherapy.

U2 - 10.1016/j.euroneuro.2021.01.004

DO - 10.1016/j.euroneuro.2021.01.004

M3 - SCORING: Journal article

C2 - 33483252

VL - 44

SP - 105

EP - 120

JO - EUR NEUROPSYCHOPHARM

JF - EUR NEUROPSYCHOPHARM

SN - 0924-977X

ER -